Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Digital health tools

Topic: Risk, prevention and care in population studies

Background The prevalence of dementia is expected to rapidly increase in the next decades, warranting innovative solutions improving diagnostics, monitoring and resource utilization to facilitate smart housing and living in the nursing home. This systematic review presents a synthesis of research on sensing technology to assess behavioral and psychological symptoms and to monitor treatment response in people with dementia. Methods The literature search included medical peer-reviewed English language publications indexed in Embase, Medline, Cochrane library and Web of Sciences, published up to the 5 th of April 2019. Keywords included MESH terms and phrases synonymous with "dementia", "sensor", "patient", "monitoring", "behavior", and "therapy". Studies applying both cross sectional and prospective designs, either as randomized controlled trials, cohort studies, and case-control studies were included. The study was registered in PROSPERO 3 rd of May 2019. Results A total of 1,337 potential publications were identified in the search, of which 34 were included in this review after the systematic exclusion process. Studies were classified according to the type of technology used, as (1) wearable sensors, (2) non-wearable motion sensor technologies, and (3) assistive technologies/smart home technologies. Half of the studies investigated how temporarily dense data on motion can be utilized as a proxy for behavior, indicating high validity of using motion data to monitor behavior such as sleep disturbances, agitation and wandering. Further, up to half of the studies represented proof of concept, acceptability and/or feasibility testing. Overall, the technology was regarded as non-intrusive and well accepted. Conclusions Targeted clinical application of specific technologies is poised to revolutionize precision care in dementia as these technologies may be used both by patients and caregivers, and at a systems level to provide safe and effective care. To highlight awareness of legal regulations, data risk assessment, and patient and public involvement, we propose a necessary framework for sustainable ethical innovation in healthcare technology. The success of this field will depend on interdisciplinary cooperation and the advance in sustainable ethic innovation. Systematic review registration PROSPERO, identifier CRD42019134313.

Key findings

Why it matters

This systematic review examined sensing technology to monitor behavioral and psychological symptoms and treatment response in people with dementia, and found the technology was regarded as non-intrusive and well accepted. It concerns monitoring tools, not a treatment, cure or prevention for Alzheimer's disease.

Study details

How this study scored 68/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 2 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 68 of 100.68 of 100 points earned32 not earned

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in pharmacology)
Journal's citation record 2 / 4 Frontiers in Pharmacology: journal h-index 242 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 3 / 4 1,337 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 A review of other studies — randomisation is not credited here
Times cited 4 / 7 Cited 97 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 10.8 citations a year over 9 year(s) since 2019
Impact for its field and year 2 / 6 Cited 2.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 2 / 4 Cited 47 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Ipsit Vihang Vahia: h-index 39 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 32116687)
Free to read 2 / 2 Free to read
Total 68 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Husebo, B. S., Heintz, H. L., Berge, L. I., Owoyemi, P., Rahman, A. T., & Vahia, IV. (2019). Sensing Technology to Monitor Behavioral and Psychological Symptoms and to Assess Treatment Response in People With Dementia. A Systematic Review. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2019.01699

Vancouver

Husebo BS, Heintz HL, Berge LI, Owoyemi P, Rahman AT, Vahia IV. Sensing Technology to Monitor Behavioral and Psychological Symptoms and to Assess Treatment Response in People With Dementia. A Systematic Review. Frontiers in pharmacology. 2019. doi:10.3389/fphar.2019.01699. PMID: 32116687.

BibTeX

@article{husebo2019-32116687,
  author  = {Husebo, B. S. and Heintz, H. L. and Berge, L. I. and Owoyemi, P. and Rahman, A. T. and Vahia, IV.},
  title   = {{Sensing Technology to Monitor Behavioral and Psychological Symptoms and to Assess Treatment Response in People With Dementia. A Systematic Review}},
  journal = {Frontiers in pharmacology},
  year    = {2019},
  doi     = {10.3389/fphar.2019.01699},
  pmid    = {32116687},
  url     = {https://doi.org/10.3389/fphar.2019.01699}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Digital health tools

Similar studies

More on Digital health tools

See all studies in Digital health tools →